$CVM
CEL SCI CORP Stock $cvm

$cvm Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-Q Financial Statement

#000165495423001725 Filed on February 14, 2023

Income Statement

Concept	2023 Q1	2022 Q4
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.093M	$2.258M
YoY Change	-30.89%	-18.19%
% of Gross Profit
Research & Development	$6.083M	$5.393M
YoY Change	-6.75%	-11.35%
% of Gross Profit
Depreciation & Amortization	$985.4K	$988.5K
YoY Change	0.63%	11.33%
% of Gross Profit
Operating Expenses	$8.176M	$7.651M
YoY Change	-14.4%	-13.49%
Operating Profit	-$8.176M	-$7.651M
YoY Change	-14.4%	-13.49%
Interest Expense	-$159.1K	-$152.8K
YoY Change	-41.44%	-266.86%
% of Operating Profit
Other Income/Expense, Net	-$7.500K	-$50.17K
YoY Change		62.94%
Pretax Income	-$8.343M	-$7.854M
YoY Change	-15.07%	-10.58%
Income Tax
% Of Pretax Income
Net Earnings	-$8.343M	-$7.854M
YoY Change	-15.07%	-10.58%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.18
Diluted Earnings Per Share	-$0.19	-$0.18
COMMON SHARES
Basic Shares Outstanding	43.74M shares	43.68M shares
Diluted Shares Outstanding		44.44M shares

Balance Sheet

Concept	2023 Q1	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$10.08M	$18.02M
YoY Change	-70.59%	-51.45%
Cash & Equivalents	$10.05M	$18.02M
Short-Term Investments	$35.62K
Other Short-Term Assets	$598.4K	$538.3K
YoY Change	-39.37%	-79.57%
Inventory	$1.894M	$1.849M
Prepaid Expenses	$598.4K	$538.3K
Receivables
Other Receivables
Total Short-Term Assets	$12.57M	$20.40M
YoY Change	-66.27%	-51.26%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.18M	$11.52M
YoY Change	-58.05%	-13.31%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.421M	$104.6K
YoY Change
Total Long-Term Assets	$25.62M	$24.15M
YoY Change	-4.7%	-13.13%
TOTAL ASSETS
Total Short-Term Assets	$12.57M	$20.40M
Total Long-Term Assets	$25.62M	$24.15M
Total Assets	$38.20M	$44.56M
YoY Change	-40.47%	-36.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.889M	$1.600M
YoY Change	43.48%	34.12%
Accrued Expenses	$1.064M	$800.8K
YoY Change	-35.82%	-11.01%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.600M	$1.600M
YoY Change	6.67%	166.67%
Total Short-Term Liabilities	$5.312M	$4.742M
YoY Change	18.72%	42.25%
LONG-TERM LIABILITIES
Long-Term Debt	$10.86M	$11.30M
YoY Change	-13.12%	-12.31%
Other Long-Term Liabilities	$125.0K	$125.0K
YoY Change	0.0%	0.0%
Total Long-Term Liabilities	$125.0K	$125.0K
YoY Change	0.0%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.312M	$4.742M
Total Long-Term Liabilities	$125.0K	$125.0K
Total Liabilities	$18.05M	$17.97M
YoY Change	-5.18%	-1.93%
SHAREHOLDERS EQUITY
Retained Earnings	-$471.1M	-$462.8M
YoY Change		8.38%
Common Stock	$437.9K	$437.3K
YoY Change		1.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$20.15M	$26.59M
YoY Change
Total Liabilities & Shareholders Equity	$38.20M	$44.56M
YoY Change	-40.47%	-36.05%

Cashflow Statement

Concept	2023 Q1	2022 Q4
OPERATING ACTIVITIES
Net Income	-$8.343M	-$7.854M
YoY Change	-15.07%	-10.58%
Depreciation, Depletion And Amortization	$985.4K	$988.5K
YoY Change	0.63%	11.33%
Cash From Operating Activities	-$7.471M	-$4.667M
YoY Change	173.5%	-2.9%
INVESTING ACTIVITIES
Capital Expenditures	$111.5K	$53.58K
YoY Change	-120.88%	214.51%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$111.5K	-$53.58K
YoY Change	-79.12%	-100.88%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-388.4K	$65.41K
YoY Change	-188.58%	-125.5%
NET CHANGE
Cash From Operating Activities	-7.471M	-$4.667M
Cash From Investing Activities	-111.5K	-$53.58K
Cash From Financing Activities	-388.4K	$65.41K
Net Change In Cash	-7.971M	-$4.655M
YoY Change	181.95%	-543.41%
FREE CASH FLOW
Cash From Operating Activities	-$7.471M	-$4.667M
Capital Expenditures	$111.5K	$53.58K
Free Cash Flow	-$7.583M	-$4.720M
YoY Change	245.0%	-2.13%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18017319	usd
CY2022Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-7650549	usd
CY2021Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-8843375	usd
CY2022Q4	us-gaap	Other General Expense OtherGeneralExpense	50171	usd
CY2021Q4	us-gaap	Other General Expense OtherGeneralExpense	0	usd
CY2022Q4	dei	Entity Central Index Key EntityCentralIndexKey	0000725363
CY2022Q4	dei	Amendment Flag AmendmentFlag	false
CY2022Q4	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
CY2022Q4	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q4	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43725636	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43448317	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Operating Lease Expense OperatingLeaseExpense	91000	usd
CY2022Q4	dei	Document Type DocumentType	10-Q
CY2022Q4	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q4	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022Q4	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q4	dei	Entity File Number EntityFileNumber	001-11889
CY2022Q4	dei	Entity Registrant Name EntityRegistrantName	CEL-SCI CORPORATION
CY2022Q4	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	CO
CY2022Q4	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-0916344
CY2022Q4	dei	Entity Address Address Line1 EntityAddressAddressLine1	8229 Boone Boulevard
CY2022Q4	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 802
CY2022Q4	dei	Entity Address City Or Town EntityAddressCityOrTown	Vienna
CY2022Q4	dei	Entity Address State Or Province EntityAddressStateOrProvince	VA
CY2022Q4	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	22182
CY2022Q4	dei	City Area Code CityAreaCode	703
CY2022Q4	dei	Local Phone Number LocalPhoneNumber	506-9460
CY2022Q4	dei	Security12b Title Security12bTitle	Common Stock
CY2022Q4	dei	Trading Symbol TradingSymbol	CVM
CY2022Q4	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2022Q4	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q4	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	usd
CY2022Q4	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q4	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q4	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-152789	usd
CY2022Q4	cvm	Modification Of Warrants ModificationOfWarrants	-171552	usd
CY2021Q4	cvm	Modification Of Warrants ModificationOfWarrants	0	usd
CY2022Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8025061	usd
CY2021Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8782606	usd
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2022Q4	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q4	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
CY2022Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43440387	shares
CY2022Q4	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43077961	shares
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	43738865	shares
CY2022Q4	us-gaap	Assets Current AssetsCurrent	20404330	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	25435916	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	10486344	usd
CY2022Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	10937797	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1839418	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1884464	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11520968	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11889029	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	202070	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	212201	usd
CY2022Q4	cvm	Supplies Used For Rd And Manufacturing Non Current SuppliesUsedForRDAndManufacturingNonCurrent	104607	usd
CY2022Q3	cvm	Supplies Used For Rd And Manufacturing Non Current SuppliesUsedForRDAndManufacturingNonCurrent	164299	usd
CY2022Q4	us-gaap	Assets Assets	44557737	usd
CY2022Q3	us-gaap	Assets Assets	50523706	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1599812	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1618290	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	800838	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	842492	usd
CY2022Q4	us-gaap	Due To Employees Current DueToEmployeesCurrent	550575	usd
CY2022Q3	us-gaap	Due To Employees Current DueToEmployeesCurrent	471488	usd
CY2022Q4	cvm	Lease Liabilities Current Portion LeaseLiabilitiesCurrentPortion	1790716	usd
CY2022Q3	cvm	Lease Liabilities Current Portion LeaseLiabilitiesCurrentPortion	1731481	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4741941	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	4663751	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	11295512	usd
CY2022Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	11721368	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1803663	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1850380	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	125000	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	125000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	17966116	usd
CY2022Q3	us-gaap	Liabilities Liabilities	18360499	usd
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43725636	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43448317	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	437256	usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	434484	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	488904967	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	486625816	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-462750602	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-454897093	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	26591621	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	32163207	usd
CY2021Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
CY2022Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44440387	shares
CY2021Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43083420	shares
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	32163207	usd
CY2022Q4	cvm	Incentive Stock Forfeited Amount IncentiveStockForfeitedAmount	-11100	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	44557737	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	50523706	usd
CY2022Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5392546	usd
CY2021Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6083167	usd
CY2022Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2258003	usd
CY2021Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2760208	usd
CY2022Q4	us-gaap	Operating Expenses OperatingExpenses	7650549	usd
CY2021Q4	us-gaap	Operating Expenses OperatingExpenses	8843375	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	56534226	usd
CY2021Q4	cvm	Warrant Exercises Amount WarrantExercisesAmount	157954	usd
CY2022Q4	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	0	usd
CY2021Q4	cvm	Equity Based Compensation Employees EquityBasedCompensationEmployees	3262296	usd
CY2022Q4	cvm	Warrant Exercises Amount WarrantExercisesAmount	447291	usd
CY2022Q4	cvm	Equity Based Compensation Employees EquityBasedCompensationEmployees	1703931	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-7853509	usd
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-8782606	usd
CY2022Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
CY2022Q4	cvm	Stock And Options Issued To Nonemployees For Service Amount StockAndOptionsIssuedToNonemployeesForServiceAmount	91623	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	50178	usd
CY2021Q4	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	52555	usd
CY2021Q4	cvm	Stock And Options Issued To Nonemployees For Service Amount StockAndOptionsIssuedToNonemployeesForServiceAmount	143160	usd
CY2021Q4	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	29835	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-7853509	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	26591621	usd
CY2021Q4	cvm	Share Issuance Costs ShareIssuanceCosts	-45965	usd
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-8782606	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	51351455	usd
CY2022Q4	us-gaap	Profit Loss ProfitLoss	-7853509	usd
CY2021Q4	us-gaap	Profit Loss ProfitLoss	-8782606	usd
CY2022Q4	us-gaap	Depreciation And Amortization DepreciationAndAmortization	988543	usd
CY2021Q4	us-gaap	Depreciation And Amortization DepreciationAndAmortization	887930	usd
CY2022Q4	us-gaap	Other Noncash Expense OtherNoncashExpense	5078	usd
CY2021Q4	us-gaap	Other Noncash Expense OtherNoncashExpense	24997	usd
CY2022Q4	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	148858	usd
CY2021Q4	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	218318	usd
CY2022Q4	us-gaap	Share Based Compensation ShareBasedCompensation	1692831	usd
CY2021Q4	us-gaap	Share Based Compensation ShareBasedCompensation	3262296	usd
CY2022Q4	cvm	Common Stock Contributed To Employee Benefit Plan CommonStockContributedToEmployeeBenefitPlan	50178	usd
CY2021Q4	cvm	Common Stock Contributed To Employee Benefit Plan CommonStockContributedToEmployeeBenefitPlan	52555	usd
CY2022Q4	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	usd
CY2021Q4	us-gaap	Gain Loss On Investments GainLossOnInvestments	-615	usd
CY2022Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
CY2021Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	30793	usd
CY2022Q4	cvm	Gain On Derivative Instruments GainOnDerivativeInstruments	0	usd
CY2021Q4	cvm	Gain On Derivative Instruments GainOnDerivativeInstruments	-364596	usd
CY2022Q4	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	111537	usd
CY2021Q4	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	144542	usd
CY2022Q4	cvm	Supplies Used For Rd And Manufacturings SuppliesUsedForRDAndManufacturings	212687	usd
CY2021Q4	cvm	Supplies Used For Rd And Manufacturings SuppliesUsedForRDAndManufacturings	-61139	usd
CY2022Q4	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-115285	usd
CY2021Q4	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-523152	usd
CY2022Q4	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	13346	usd
CY2021Q4	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	95685	usd
CY2022Q4	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	79087	usd
CY2021Q4	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	209046	usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4666649	usd
CY2021Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4805946	usd
CY2022Q4	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	0	usd
CY2021Q4	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	6152000	usd
CY2022Q4	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	53580	usd
CY2021Q4	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	17036	usd
CY2022Q4	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
CY2021Q4	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	22741	usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-53580	usd
CY2021Q4	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	6112223	usd
CY2022Q4	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	9010	usd
CY2021Q4	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	32800	usd
CY2022Q4	cvm	Proceeds From Exercises Of Warrants And Options ProceedsFromExercisesOfWarrantsAndOptions	447291	usd
CY2021Q4	cvm	Proceeds From Exercises Of Warrants And Options ProceedsFromExercisesOfWarrantsAndOptions	117200	usd
CY2022Q4	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	372871	usd
CY2021Q4	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	340908	usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	65410	usd
CY2021Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-256508	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-4654819	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	1049769	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22672138	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36060148	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18017319	usd
CY2022Q4	cvm	Property And Equipment Included In Current Liabilities PropertyAndEquipmentIncludedInCurrentLiabilities	105318	usd
CY2022Q4	cvm	Finance Lease Obligation Included In Accounts Payable FinanceLeaseObligationIncludedInAccountsPayable	1853	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	37109917	usd
CY2021Q4	cvm	Property And Equipment Included In Current Liabilities PropertyAndEquipmentIncludedInCurrentLiabilities	469005	usd
CY2022Q4	cvm	Prepaid Consulting Services Paid With Issuance Of Common Stock PrepaidConsultingServicesPaidWithIssuanceOfCommonStock	91623	usd
CY2021Q4	cvm	Finance Lease Obligation Included In Accounts Payable FinanceLeaseObligationIncludedInAccountsPayable	771	usd
CY2021Q4	cvm	Prepaid Consulting Services Paid With Issuance Of Common Stock PrepaidConsultingServicesPaidWithIssuanceOfCommonStock	233753	usd
CY2022Q4	cvm	Exercise Of Derivative Liabilities ExerciseOfDerivativeLiabilities	0	usd
CY2021Q4	cvm	Exercise Of Derivative Liabilities ExerciseOfDerivativeLiabilities	70589	usd
CY2022Q4	cvm	Financing Costs Included In Current Liabilities FinancingCostsIncludedInCurrentLiabilities	0	usd
CY2021Q4	cvm	Financing Costs Included In Current Liabilities FinancingCostsIncludedInCurrentLiabilities	13165	usd
CY2022Q4	us-gaap	Interest Paid Net InterestPaidNet	277853	usd
CY2021Q4	us-gaap	Interest Paid Net InterestPaidNet	290212	usd
CY2022Q4	cvm	Supplies Used For Rd And Manufacturing Policytextblock SuppliesUsedForRDAndManufacturingPolicytextblock	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Supplies used for R&D and manufacturing –</em> Supplies are consumable items kept on hand to support the Company’s R&D and manufacturing operations. Supplies are recorded at cost and are charged to expense as they are used in operations.</p>
CY2022Q4	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P17Y
CY2022Q4	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Use of Estimates</em> – The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management’s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities, deferred tax assets and the related valuation allowance, and the valuation of derivative liabilities. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year. However, in regard to the valuation of derivative liabilities determined using the Black-Scholes option pricing model, significant fluctuations may materially affect the financial statements in a given year. Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms. The Company considers the estimates used in valuing the derivative liabilities, stock options and the lease assets and liabilities to be significant.</p>
CY2022Q4	cvm	Liquiditydisclosure Textblock LiquiditydisclosureTextblock	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">B. <span style="text-decoration:underline">LIQUIDITY</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction and expansion of manufacturing and laboratory facilities and participation in clinical trials. The Company has funded such costs primarily with proceeds from loans and the public and private sale of its securities. The Company will be required to raise additional capital or find additional long-term financing to continue with its efforts to bring Multikine to market. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to obtain approval from the U.S. Food and Drug Administration (FDA) for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. The Company believes there is a high likelihood that it will continue to receive funds from private and public offerings and warrant exercises similar to the way it has funded operations in the past. However, there can be no assurance that the Company will be able to raise sufficient capital to support its operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">To finance the Company through marketing approval, the Company plans to raise additional capital in the form of warrant exercises, corporate partnerships, and debt and/or equity financings. The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because it showed great survival benefit in the Phase 3 study in one of the two treatment arms for advanced primary head and neck cancer. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all. If the Company does not raise the necessary amounts of money, it may have to curtail its operations until such time as it is able to raise the required funding.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Due to the Company’s recurring losses from operations and future liquidity needs, there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Impact of the COVID-19 Pandemic</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In response to the global outbreak of COVID-19 and the World Health Organization’s classification of the outbreak as a pandemic, the Company continues to take the necessary precautions to ensure the safety of its employees and to minimize interruptions to its operations. Management follows the Centers for Disease Control and Prevention’s (“CDC”) guidance and the recommendations and restrictions provided by state and local authorities. The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. As such, it is uncertain as to the full magnitude of impact the pandemic will have on the Company’s financial condition, liquidity and future results of operations. Management is actively monitoring the risks to public health and the impact of overall global business activity on its financial condition, liquidity, operations, suppliers, industry, and workforce.</p>
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	138400	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2500	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	251000	shares
CY2021Q4	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	6500	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	96832	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	13000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	45400	shares
CY2022Q4	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1692831	usd
CY2021Q4	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	3262296	usd
CY2022Q4	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	148858	usd
CY2021Q4	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	218318	usd
CY2022Q4	cvm	Fair Value Of Series Zwarrants FairValueOfSeriesZwarrants	0	usd
CY2021Q4	cvm	Fair Value Of Series Zwarrants FairValueOfSeriesZwarrants	64787	usd
CY2022Q4	cvm	Fair Value Of Series Aa Warrants FairValueOfSeriesAaWarrants	0	usd
CY2021Q4	cvm	Fair Value Of Series Aa Warrants FairValueOfSeriesAaWarrants	274635	usd
CY2022Q4	cvm	Fair Value Of Series Cc Warrants FairValueOfSeriesCcWarrants	0	usd
CY2021Q4	cvm	Fair Value Of Series Cc Warrants FairValueOfSeriesCcWarrants	24372	usd
CY2022Q4	cvm	Fair Value Of Series Hh Warrants FairValueOfSeriesHhWarrants	0	usd
CY2021Q4	cvm	Fair Value Of Series Hh Warrants FairValueOfSeriesHhWarrants	802	usd
CY2022Q4	cvm	Gain Loss On Derivative Instruments Net Pretax1 GainLossOnDerivativeInstrumentsNetPretax1	0	usd
CY2021Q4	cvm	Gain Loss On Derivative Instruments Net Pretax1 GainLossOnDerivativeInstrumentsNetPretax1	364596	usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	3015000	usd
CY2022Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	3446000	usd
CY2022Q4	cvm	Warrants Exercised WarrantsExercised	217752	shares
CY2022Q4	cvm	Proceeds From Exercise ProceedsFromExercise	447291	usd
CY2021Q4	cvm	Warrants Exercised WarrantsExercised	14500	shares
CY2021Q4	cvm	Proceeds From Exercise ProceedsFromExercise	33740	usd
CY2022Q4	cvm	Incremental Cost Deemed Dividend IncrementalCostDeemedDividend	172000	usd
CY2022Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0	usd
CY2021Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	437380	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	0	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	0	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Sales FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales	0	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Sales FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales	70589	usd
CY2022Q4	cvm	Fair Value Measured On Recurring Basis Gain Loss Included Earnings FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings	0	usd
CY2021Q4	cvm	Fair Value Measured On Recurring Basis Gain Loss Included Earnings FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings	-364596	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	2195	usd
CY2022Q4	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	35600000	usd
CY2022Q4	cvm	Net Of Discount NetOfDiscount	11800000	usd
CY2022Q4	cvm	Weighted Average Time To Maturity WeightedAverageTimeToMaturity	P5Y29D
CY2022Q4	cvm	Current Balance CurrentBalance	200000	usd
CY2022Q4	cvm	Finance Lease Liability Payments Due Remainder Of Year FinanceLeaseLiabilityPaymentsDueRemainderOfYear	1937000	usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	2655000	usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	2741000	usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	2832000	usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	2923000	usd
CY2022Q4	cvm	Net Present Value Of Lease Finance Lease Obligations NetPresentValueOfLeaseFinanceLeaseObligations	12909000	usd
CY2022Q4	cvm	Operating Lease Right Of Use Assets OperatingLeaseRightOfUseAssets	1800000	usd
CY2022Q3	cvm	Operating Lease Right Of Use Assets OperatingLeaseRightOfUseAssets	1900000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2000000.0	usd
CY2021Q1	cvm	Current Portion Of Operating Lease Obligation CurrentPortionOfOperatingLeaseObligation	200000	usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	252000	usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	16355000	usd
CY2022Q4	cvm	Increase In Right Of Use Asset And Liability IncreaseInRightOfUseAssetAndLiability	1100000	usd
CY2022Q4	us-gaap	Operating Lease Expense OperatingLeaseExpense	91000	usd
CY2022Q4	us-gaap	Operating Lease Payments OperatingLeasePayments	85000	usd
CY2021Q4	us-gaap	Operating Lease Payments OperatingLeasePayments	66000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0910	pure
CY2022Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
CY2022Q4	cvm	Lessee Operating Lease Liability Payments Due Remainder Of Year LesseeOperatingLeaseLiabilityPaymentsDueRemainderOfYear	262000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	357000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	366000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	287000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	277000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	285000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1040000	usd
CY2022Q4	cvm	Lessee Operating Lease Liability Payments LesseeOperatingLeaseLiabilityPayments	2874000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	893000	usd
CY2022Q4	cvm	Cfgh cfgh	1981000	usd
CY2022Q4	cvm	Patent Impairment Charges PatentImpairmentCharges	0	usd
CY2021Q4	cvm	Patent Impairment Charges PatentImpairmentCharges	31000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	28000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	30000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	28000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	24000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	21000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	17000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive	54000	usd
CY2022Q4	us-gaap	Other Indefinite Lived Intangible Assets OtherIndefiniteLivedIntangibleAssets	202000	usd
CY2022Q4	cvm	Schedule Of Reconciliation Of The Numerators And Denominators Of The Basic And Diluted Per Share Computationstabletextblock ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three months ended December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Loss per share – basic</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Net loss available to common shareholders - basic</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(8,025,061</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(8,782,606</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Weighted average shares outstanding - basic</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">43,440,387</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">43,077,961</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">Basic loss per common share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.18</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.20</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Loss per share – diluted</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Net loss available to common shareholders - basic</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(8,025,061</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(8,782,606</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Gain on derivatives (1)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(25,114</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:left;">Net loss available to common shareholders - diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(8,025,061</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(8,807,720</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Weighted average shares outstanding - basic</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">43,440,387</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">43,077,961</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Incremental shares underlying dilutive - warrants and options (1)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">5,459</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Weighted average shares outstanding – diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">43,440,387</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">43,083,420</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">Diluted loss earnings per common share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.18</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.20</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table>
CY2022Q4	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	-8025061	usd
CY2021Q4	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	-8782606	usd
CY2022Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43440387	shares
CY2021Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43077961	shares
CY2021Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
CY2022Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8025061	usd
CY2021Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8782606	usd
CY2022Q4	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0	usd
CY2021Q4	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-25114	usd
CY2022Q4	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-8025061	usd
CY2021Q4	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-8807720	usd
CY2022Q4	cvm	Weighted Average Number Of Share Outstanding Basics And Diluted WeightedAverageNumberOfShareOutstandingBasicsAndDiluted	43440387	shares
CY2021Q4	cvm	Weighted Average Number Of Share Outstanding Basics And Diluted WeightedAverageNumberOfShareOutstandingBasicsAndDiluted	43077961	shares
CY2021Q4	cvm	Incremental Shares Underlying Dilutive Warrants And Options IncrementalSharesUnderlyingDilutiveWarrantsAndOptions	5459	shares
CY2022Q4	cvm	Weighted Average Shares Outstanding Diluted WeightedAverageSharesOutstandingDiluted	43440387	shares
CY2021Q4	cvm	Weighted Average Shares Outstanding Diluted WeightedAverageSharesOutstandingDiluted	43083420	shares
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2021Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
CY2022Q4	cvm	Schedule Of Anti Dilutive Securitiestabletextblock ScheduleOfAntiDilutiveSecuritiestabletextblock	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options and Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,917,352</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,477,966</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested Restricted Stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">149,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">151,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">14,066,602</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">10,629,216</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2022Q4	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14066602	shares
CY2021Q4	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10629216	shares

Files In Submission

Name	View Source	Status
cvm-20221231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cvm-20221231_cal.xml	Edgar Link	unprocessable
0001654954-23-001725-index-headers.html	Edgar Link	pending
0001654954-23-001725-index.html	Edgar Link	pending
0001654954-23-001725.txt	Edgar Link	pending
0001654954-23-001725-xbrl.zip	Edgar Link	pending
cvm-20221231.xsd	Edgar Link	pending
cvm_10q.htm	Edgar Link	pending
cvm_ex31.htm	Edgar Link	pending
cvm_ex32.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
cvm_10q_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
cvm-20221231_def.xml	Edgar Link	unprocessable
cvm-20221231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CVM
CEL SCI CORP Stock $cvm

2023 Q1 Form 10-Q Financial Statement

#000165495423001725 Filed on February 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CVM CEL SCI CORP Stock $cvm

2023 Q1 Form 10-Q Financial Statement

#000165495423001725 Filed on February 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CVM
CEL SCI CORP Stock $cvm